DTx for Substance Use Disorders: Alcohol, Tobacco, and Opioids
Substance Use Disorders (SUDs) represent a pressing global health challenge, and Digital Therapeutics are emerging as critical tools in delivering scalable, evidence-based treatment—especially for alcohol, tobacco, and opioid use.
The FDA-approved reSET® and reSET-O® programs by Pear Therapeutics are landmark examples of PDTs specifically designed for SUDs. These platforms use CBT-based modules, contingency management, and motivational interviewing techniques to promote abstinence and improve treatment retention.
For opioid use disorder (OUD), reSET-O is designed to be used alongside medication-assisted therapy (MAT), such as buprenorphine. It addresses behavioral aspects while supporting medication adherence—an essential combination for sustained recovery.
Tobacco cessation programs increasingly use DTx to provide interactive coaching, craving tracking, and real-time support via apps. Alcohol use DTx platforms focus on reducing harm and managing relapse triggers through adaptive modules and data-driven nudges.
DTx solutions offer anonymity, convenience, and 24/7 support—crucial for patients reluctant to seek in-person care due to stigma or access barriers. Moreover, integration with wearables and digital breathalyzers enhances self-monitoring and accountability.